Biosynthesis of apoprosthetic carotenoids by controlling oxidative stress
Genetically modifying host cells, including the mevalonate pathway, lycopene pathway and α-ionone pathway, as well as hydroperoxide reductase or catalase genes, improves the biosynthesis of α-ionone production The rate of this solution solves the problem of limited application in the flavor and fragrance industry and achieves efficient production.
Patent Information
- Application Number
- CN202380024756.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-01
- Filing Date
- 2023-03-01
- Publication Date
- 2024-11-08
Smart Images

Figure BDA0005020226780000191 
Figure BDA0005020226780000201 
Figure BDA0005020226780000202
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Singapore application number 10202202053S filed on March 1, 2022, the contents of which are hereby incorporated by reference in their entirety for all purposes. Technical Field
[0003] The present invention belongs to the field of biotechnology. The present invention relates to an improved method for producing apocarotenoids. In particular, the present invention relates to the biosynthesis of α-ionone using a genetically modified host organism.
[0004] Sequence Listing
[0005] This application contains a sequence listing, which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy was created on March 1, 2023, named 78696SG2_Sequence Listing.xml, and is 20kb in size. Background Art
[0006] Apocarotenoids are a class of compounds generated by the oxidative cleavage of carotenoids. Apocarotenoids are widely distributed in bacteria, fungi, plants and animals. Apocarotenoids have a variety of biological functions and are precursors of hormones (abscisic acid, strigolactones), pigments, signaling compounds and aromatic compounds. These carotenoid-derived aromatic compounds include ionones (α- and β-ionone), which are a group of natural ketone compounds composed of 13 carbons with a monocyclic terpenoid backbone, found in various flowers and fruits, including roses, osmanthus, orris root and raspberries. α- and β-ionones are produced by the oxidation of carotenoids such as α-carotene or ε-carotene by carotenoid cleavage oxygenases. In particular, α-ionone has a violet-like aroma, raspberry and blackberry odors and an extremely low odor threshold of 0.4-3.2 ppb (parts per billion). These properties of α-ionone make it widely used in the flavor and fragrance industry.
[0007] α-ionone has high commercial value and demand, but due to its extremely low abundance, large-scale extraction from natural materials is not feasible, so the production of commercial α-ionone is mainly through chemical synthesis.
[0008] Therefore, it is necessary to improve the existing apocarotenoid biosynthesis methods to achieve higher yields. Summary of the invention
[0009] In one aspect, a host cell is provided comprising one or more vectors comprising a polynucleotide sequence encoding:
[0010] one or more genes of the mevalonate pathway;
[0011] one or more genes of the lycopene pathway;
[0012] one or more genes of the α-ionone pathway; and
[0013] One or more hydroperoxide reductase or catalase genes.
[0014] In another aspect, a method of producing one or more apocarotenoids is provided, comprising culturing a host cell described herein in a culture medium.
[0015] In another aspect, a kit for producing one or more apocarotenoids is provided, wherein the kit comprises a host cell as described herein and instructions for use.
[0016] definition
[0017] The term "carotenoid" as used herein refers to a class of naturally occurring pigments synthesized by plants, animals, algae and microorganisms. Carotenoids have an electron-rich polyene chain structure with 9 or more conjugated bonds and have photoprotective, light-harvesting and antioxidant properties.
[0018] As used herein, the term "apocarotenoids" refers to a class of naturally occurring compounds derived from carotenoids by enzyme-catalyzed oxidative cleavage. These enzymes are carotenoid cleavage dioxygenases (CCDs).
[0019] The term "variant" as used herein refers to a modification of a DNA sequence. Modification of a DNA sequence includes mutation, truncation, translocation, substitution, deletion and insertion, thereby resulting in a change in gene activity.
[0020] The DNA region is usually located near the gene transcription start site and upstream of the DNA. Promoters can be inducible or non-inducible. The term "inducible promoter" used herein refers to a promoter that can be regulated in response to a specific stimulus (also referred to as an inducer). Promoter systems can be modified to be inducible. Examples of inducible promoter systems include Tet-on systems, Tet-off systems, T7 systems, Trp systems, Tac systems, λcI857-PL systems, bacterial EL222 systems, and Lac systems. A promoter can also be a constitutive promoter, which is a promoter that is always active.
[0021] As used herein, the term "overexpression" refers to an increase in the expression of a gene or protein in the context of a gene or protein. Overexpression may also refer to the expression of a gene when the gene is not expressed. It is generally understood that the overexpression of a gene or protein is relative to the baseline expression of the gene or protein. The baseline expression of a gene or protein will be understood to refer to the expression level of an unmutated gene or wild-type gene, or, in the case of a gene not expressed, to the expression level of background / noise. In this case, ahpC / F or KatG is overexpressed, and it is understood that the expression of ahpC / F and KatG increases (i.e., extra copies of ahpC / F and KatG) relative to the basal levels of ahpC / F and KatG in the host cell.
[0022] As used herein, the term "about" generally refers to + / -5% of the value, + / -4% of the value, more generally + / -3% of the value, more generally + / -2% of the value, even more generally + / -1% of the value, and even more generally + / -0.5% of the value in the context of component concentrations and compound percentages. Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description of the range format is merely for convenience and brevity and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and single values within the range. For example, the description of the range 1-6 should be considered to have specifically disclosed sub-ranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6 within the range, as well as single digits such as 1, 2, 3, 4, 5 and 6. This applies regardless of how large the range is.
[0023] BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and accompanying drawings, in which:
[0025] Figure 1A schematic diagram of the α-ionone biosynthetic pathway is shown. The pathway contains 4 modules: the mevalonate pathway (modules 1 and 2), the lycopene pathway (module 3), and the α-ionone pathway (module 4). The expressed genes encode the following enzymes: atoB; acetoacetyl-CoA thiolase; hmgS, HMG-CoA synthase; thmgR, truncated HMG-CoA reductase; mevk, mevalonate kinase; pmk, phosphomevalonate kinase; pmd, mevalonate pyrophosphate decarboxylase; idi, IPP isomerase; ispA, FPP synthase; crtE, GGPP synthase; crtB, phytoene synthase; crtI, lycopene-β-cyclase; lcyE, lycopene-ε-cyclase. Abbreviations of compounds: CCD1, carotenoid cleavage dioxygenase 1; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A; MVA, mevalonate; MVAP, mevalonate phosphate; MVAPP, mevalonate diphosphate; IPP, isopentenyl pyrophosphate; DMAPP, dimethylallyl pyrophosphate; GPP, geranyl pyrophosphate; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate. Dashed arrows indicate various enzymatic steps.
[0026] Figure 2 The titer, content and optical density of α-ionone produced by different strains are shown. Figure 2 A shows AI-2211, A: 1 ml defined medium + 200 μl dodecane, 300 rpm (83.55 mg / l), through a Snape tube. B: 10 ml defined medium + 10 ml dodecane, 100 rpm (39.15 mg / l), through a flask. C: 10 ml defined medium + 10 ml dodecane, 300 rpm (19.25 mg / l), through a flask. Figure 2 B shows AI_2211, AI_3211, AI_2217 and AI_2218 in 10 ml defined medium + 10 ml dodecane through flasks at 100 rpm and 300 rpm. The data are the average of duplicate data.
[0027] Figure 3 ROS-Glo showing H2O2 production by AI_2211 and AI_2218 at 250 rpm or 500 rpm via RTS TM Detection signal. After incubation for 1.5 hr, 100 μl of each test of the mixed culture of AI_2211 and AI_2218 was plated in a 96-well white cell culture plate, and 100 μl of ROS-GloTM Detection Solution was added to the wells. Luminescence was measured using a Multi+ luminometer. The average relative light unit (RLU) and standard deviation of four replicate samples were calculated.
[0028] Figure 4 The ratio of MHO / α-ionone produced by AI_2211 and AI_2218 at 100 rpm and 300 rpm by cell pellets is shown. Multiples of AI_2211 100 rpm (0.24), 300 rpm (0.48) and AI_2218 100 rpm (0.26), 300 rpm (0.22). The color of the pellets at 100 rpm for AI_2211 and AI_2218 was orange; AI_2211 was colorless at 300 rpm and AI_2218 was yellow at 300 rpm.
[0029] Figure 5 The ionone production and optical density (OD) of the bioreactor using AI_2218 are shown. 600 The end point is 127hr, OD 600 It was 229.3, the titer of α-ionone was 679.9 mg / l, the titer of β-ionone was 35.2 mg / l, and the titer of ψ-ionone was 105.8 mg / l.
[0030] Figure 6 Proposed schemes are described that illustrate how H2O2 affects α-ionone production. (i) Pathway without oxidative stress. Low H2O2 production due to low oscillation speed. (ii) Pathway with oxidative stress. High oscillation speed and high H2O2. H2O2 degrades lycopene (a substrate for CCD1) to MHO and may degrade CCD1 (which contains a molecule in the active site that can be oxidized to Fe by H2O2). 3+ Key Fe 2+ (iii) A pathway without oxidative stress due to the elimination of H2O2 by AhpC / F. Lycopene is not degraded to MHO and therefore CCD1 is not inactivated, which will further increase α-ionone production.
[0031] Figure 7 Strains AI_2211 and AI_2218 producing α-ionone are shown. AI_2211, module 1: Tm2-AHT+CCD1, module 2: Tm3-MPPI, module 3: Tm1BIA+MbGGPPs and module 4: Tm1-LTOM. AI_2218, module 1: Tm2+CCD1, module 2: Tm3-MPPI, module 3: Tm1-MbGGPPs, module 4: Tm1-LTOM-ahpC / F.
[0032] Figure 8 Comparison of α-ionone titers of different strains AI_0000, AI_2211 and AI_2218 is shown: AI_0000 (24.1 mg / l), AI_2211 (13 mg / l) and AI_2218 (38.4 mg / l). All strains were grown in 10 ml defined medium + 10 ml dodecane, by flask, at a shaking speed of 300 rpm. Data are the average of replicates.
[0033] Fig. 9 The effect of H2O2 on LcyE activity leading to lycopene accumulation is depicted (i) A pathway without oxidative stress. Due to the low oscillation speed, H2O2 production is low. (ii) H2O2 can oxidize the reduced FAD of LcyE, inactivating the enzyme. Lycopene then accumulates and is cleaved into MHO by CCD1, which may cause CCD1 (which contains a molecule in the active site that can be oxidized to Fe by H2O2) to accumulate. 3+ Key Fe 2+ (iii) A pathway without oxidative stress due to the elimination of H2O2 by AhpC / F. Lycopene is not degraded to MHO and therefore CCD1 is not inactivated, which will further increase α-ionone production.
[0034] Fig.10 α-ionone production of AI_2211 (Tm2+CCD1 / Tm3-MPPI / Tm1-MbGGPPs / Tm1-LTOM) and AI_3211 (Tm2-AHT / Tm3-MPPI / Tm1-MbGGPPs / Tm1-LTOM) is shown. AI_2211, 100 rpm (42 mg / l), 300 rpm (11 mg / l). AI_3211, 100 rpm (17 mg / l), 300 rpm (25 mg / l). Both were performed by flask in 10 ml defined medium + 10 ml dodecane. Data are the average of replicate data.
[0035] Fig.11 α-ionone production in strains overexpressing catalase genes: catalase G (katG), alkyl hydroperoxide reductase (ahpC / F) is shown. AI_2217 (Tm2+CCD1 / Tm3-MPPI / Tm1-MbGGPPs / Tm1-LTOM-katG)
[0036] AI_2218(Tm2+CCD1 / Tm3-MPPI / Tm1-MbGGPPs / Tm1-LTOM-ahpC / F
[0037] AI_2217, 100 rpm (35 mg / l), 300 rpm (21 mg / l). AI_2218, 100 rpm (27 mg / l), 300 rpm (38 mg / l). Both were performed in 10 ml defined medium + 10 ml dodecane by flask. The data are the average of replicate data.
[0038] Fig.12 The ionone titers of different strains are shown: AI_2211, AI_3211, AI_2217 and AI_2218. AI_2211, 100 rpm (49 mg / l), 300 rpm (14 mg / l). AI_3211, 100 rpm (29 mg / l), 300 rpm (35 mg / l). AI_2217, 100 rpm (45 mg / l), 300 rpm (24 mg / l). AI_2218, 100 rpm (39 mg / l), 300 rpm (42 mg / l). All strains were carried out by flask in 10 ml defined medium + 10 ml dodecane. Data are the average of replicate data. DETAILED DESCRIPTION
[0039] In a first aspect, the present invention relates to a host cell comprising one or more vectors comprising a polynucleotide sequence encoding:
[0040] one or more genes of the mevalonate pathway;
[0041] one or more genes of the lycopene pathway;
[0042] one or more genes of the α-ionone pathway; and
[0043] One or more hydroperoxide reductase or catalase genes.
[0044] The host cell may contain any number of vectors that allow expression of one or more genes of the mevalonate, lycopene, α-ionone pathways, and a hydroperoxide reductase or catalase gene. For example, the host cell may contain one vector, two vectors, three vectors, four vectors, five vectors, six vectors, or seven vectors. One skilled in the art will recognize that one or more genes of the mevalonate pathway, one or more genes of the lycopene pathway, one or more genes of the α-ionone pathway, and one or more hydroperoxide reductase or catalase genes may be located on one or more vectors in different combinations. In one example, one or more genes of the mevalonate pathway may be located on one vector, one or more genes of the lycopene pathway may be located on another vector, one or more genes of the α-ionone pathway may be located on another vector, and one or more hydroperoxide reductase or catalase genes may be located on yet another vector. In another example, one or more genes of the mevalonate pathway and one or more genes of the lycopene pathway can be located on one vector, one or more genes of the lycopene pathway and the α-ionone pathway can be located on another vector, one or more genes of the mevalonate pathway and the α-ionone pathway can be located on another vector, and one or more genes of the lycopene pathway and one or more hydroperoxide reductase or catalase genes can be located on yet another vector. In yet another example, one or more genes of the mevalonate pathway and the α-ionone pathway can be located on one vector, one or more genes of the mevalonate pathway and the α-ionone pathway can be located on another vector, one or more genes of the lycopene pathway can be located on another vector, and one or more hydroperoxide reductase or catalase genes can be located on yet another vector. In yet another example, one or more genes of the mevalonate pathway can be located on two vectors, one or more genes of the lycopene pathway can be located on one vector, and one or more hydroperoxide reductase or catalase genes can still be located on yet another vector. It should be understood that the above examples are not exhaustive and are merely intended to illustrate that genes may be located on one or more vectors in various combinations.
[0045] In one example, the host cell comprises four vectors. In one example, the host cell comprises:
[0046] a) a first vector comprising a polynucleotide sequence encoding one or more genes of the mevalonate pathway;
[0047] b) a second vector comprising a polynucleotide sequence encoding one or more genes of the mevalonate pathway;
[0048] c) a third vector comprising a polynucleotide sequence encoding one or more genes of the lycopene pathway; and
[0049] d) a fourth vector comprising a polynucleotide sequence encoding one or more genes of the α-ionone pathway and a polynucleotide sequence encoding one or more hydroperoxide reductase or catalase genes.
[0050] In one example, one or more genes of the mevalonate pathway can include, but are not limited to, hmgS, atoB, hmgR, mevK, pmk, pmd, and idi. In one example, the hmgR gene is truncated.
[0051] In one example, the one or more genes of the lycopene pathway can include, but are not limited to, crtBI, crtB, crtI, farnesyl diphosphate synthase gene, and geranylgeranyl diphosphate synthase (GGPPs) gene.
[0052] In one example, the GGPPs gene is isolated from a prokaryotic organism. In one example, the prokaryotic organism is an archaeon. The archaeon may be Methanocaldococcus jannaschii or Methanococcusmaripaludis. In another example, the prokaryotic organism may be a bacterium. The bacterium may be Methanobacterium or Deinococcus radioduran. In a preferred example, the bacterium is Methanobacterium.
[0053] In one example, the one or more genes of the α-ionone pathway can include, but are not limited to, a lycopene cyclase gene and a CCD gene.
[0054] In addition, in addition to one or more genes of the α-ionone pathway, the host cell may also contain a polynucleotide sequence encoding one or more additional CCD genes. The additional CCD genes may be located on the first, second, third, fourth vector or a combination thereof. Thus, the host cell may contain a total of one, two, three, four or more CCD gene copies.
[0055] In one example, the host cell comprises an additional copy of a CCD gene, wherein the polynucleotide sequence encoding the additional CCD gene is located on a vector comprising one or more genes of the mevalonate pathway.
[0056] In one example, the host cell comprises two additional copies of a CCD gene, wherein the polynucleotide sequences encoding the two additional CCD genes are located on a vector comprising one or more genes of the α-ionone pathway.
[0057] In another example, the host cell comprises two additional CCD gene copies, wherein the polynucleotide sequences encoding the two additional CCD genes of the α-ionone pathway are located on one vector comprising one or more genes of the mevalonate pathway and on another vector comprising one or more genes of the lycopene pathway and the α-ionone pathway. In yet another example, the host cell comprises three additional CCD gene copies, wherein the polynucleotide sequences encoding the three additional CCD genes are located on one vector comprising one or more genes of the mevalonate pathway, on another vector comprising one or more genes of the lycopene pathway and on yet another vector comprising one or more genes of the α-ionone pathway. In yet another example, the host cell comprises four additional CCD gene copies, wherein the polynucleotide sequences encoding the four additional CCD1 genes of the α-ionone pathway are located on two vectors comprising one or more genes of the mevalonate pathway and on one vector comprising one or more genes of the α-ionone pathway and one or more hydroperoxide reductase or catalase genes. In yet another example, the host cell comprises four additional CCD gene copies, wherein the polynucleotide sequences encoding four additional CCD1 genes of the α-ionone pathway are located on one vector comprising one or more genes of the lycopene pathway, and on another vector comprising one or more genes of the α-ionone pathway and one or more hydroperoxide reductase or catalase genes. It should be understood that these examples are not exhaustive, and one or more additional CCD gene copies can be located on any vector or combination thereof.
[0058] In one example, the CCD gene can be a CCD1 or CCD4 gene. In a preferred example, the CCD gene is a CCD1 gene.
[0059] In one example, one or more CCD1 genes are isolated from plants. Plants may include Osmanthus fragrans, Arabidopsis thaliana, Vitis vinifera and Petunia hybrid. In a preferred example, one or more CCD1 genes are isolated from Osmanthus fragrans (OfCCD1). One or more OfCCD1 genes comprise the polypeptide sequence shown in SEQ ID NO: 1.
[0060] In one example, one or more OfCCD1 genes are mutated in the loop of the active site. The OfCCD gene can mutate at one or more amino acid positions in the active site loop. The OfCCD gene can mutate at one amino acid position, two amino acid positions, three amino acid positions, four amino acid positions, five amino acid positions, and six amino acid positions in the active site loop. In a preferred example, the OfCCD1 mutations are located at three amino acid positions in the active site loop. The mutations include substitution of lysine at position 425 with serine, substitution of aspartic acid at position 424 with asparagine, and substitution of lysine at position 428 with alanine. The mutated OfCCD1 gene can comprise the polynucleotide sequence shown in SEQ ID NO:2.
[0061] In one example, one or more OfCCD1 are truncated.
[0062] One or more CCD genes can be fused to a protein or peptide (fusion partner) at the N-terminus. It should generally be understood that a fusion partner refers to a protein or peptide fused to another protein or peptide. In one example, the N-terminal fusion partner may include, but is not limited to, small ubiquitin-like modified proteins, maltose binding protein, and thioredoxin (trxA). In a preferred example, the N-terminal fusion partner is trxA. In one example, OfCCD1 is fused to trxA.
[0063] In one example, one or more of the OfCCD1 and trxA genes are overexpressed. The OfCCD1 gene can be expressed together with the trxA gene, and in one example, when the OfCCD1 gene is fused with the trxA gene, the trxA gene can be overexpressed together with the OfCCD1 gene.
[0064] When the host cell contains more than one CCD gene copy, each CCD gene copy can be a wild-type CCD gene or a mutant of a CCD gene or a combination thereof. The polynucleotide sequence encoding one or more CCD genes can be located on one or more vectors. In one example, a vector comprising one or more genes of the mevalonate pathway comprises a polynucleotide sequence of a wild-type OfCCD1 gene fused to TrxA, and a vector comprising one or more genes of the α-ionone pathway and one or more hydroperoxide reductase or catalase genes comprises a polynucleotide sequence of a mutant OfCCD1 gene fused to TrxA. In another example, a vector comprising one or more genes of the mevalonate pathway comprises a polynucleotide sequence of a wild-type CCD4 gene, and a vector comprising one or more genes of the lycopene pathway comprises a polynucleotide sequence of a wild-type OfCCD1 gene. In another example, a vector comprising one or more genes of the lycopene pathway comprises a polynucleotide sequence of a wild-type OfCCD1 gene, and a vector comprising one or more genes of the lycopene pathway comprises a polynucleotide sequence of a mutant OfCCD1 gene. In yet another example, the vector comprising one or more genes of the mevalonate pathway comprises the polynucleotide sequence of a mutant OfCCD1 gene, and the vector comprising one or more genes of the lycopene pathway comprises the polynucleotide sequence of a truncated OfCCD1. In yet another example, the vector comprising one or more genes of the mevalonate pathway comprises the polynucleotide sequence of a wild-type OfCCD1 gene, the vector comprising one or more genes of the lycopene pathway comprises the polynucleotide sequence of a mutant OfCCD1 gene, and the vector comprising one or more genes of the α-ionone pathway and one or more hydroperoxide reductase or catalase genes comprises the polynucleotide sequence of a CCD4 gene. It should be understood that these examples are not exhaustive and that the one or more vectors in the host cell may comprise any CCD gene described herein.
[0065] In one example, the lycopene cyclase gene is a lycopene epsilon cyclase (LCYe) gene. In one example, the LCYe gene is isolated from a plant, including but not limited to lettuce (Lactuca sativa), Arabidopsis thaliana (Arabidopsisthaliana), tobacco (Nicotiana tabacum) and cabbage (Brassica oleracea var. capitata). In a preferred example, LCYe is isolated from lettuce.
[0066] The LCYe gene comprises one or more mutations, resulting in truncation of the LCYe protein. In one example, the LCYe gene is truncated at the N-terminus. In one example, LCYe is truncated from amino acids 1-50. In one example, the truncated LCYe comprises the polynucleotide sequence shown in SEQ ID NO: 3.
[0067] In one embodiment, one or more hydroperoxide reductase or catalase genes are isolated from a prokaryotic organism. In a preferred embodiment, the prokaryotic organism is Escherichia coli (E. coli).
[0068] In one example, the hydroperoxide reductase gene isolated from E. coli is alkyl hydroperoxide reductase (ahpC / F). In another example, the catalase gene isolated from E. coli is catalase G (KatG).
[0069] In one example, ahpC / F and / or KatG are overexpressed. Overexpression can be achieved by various means generally known in the art. In one example, overexpression can be achieved by expressing more than one copy of ahpC / F and / or KatG genes in a host cell. In some examples, a host cell can endogenously express a copy of ahpC / F and / or KatG in the host cell genome and express one or more additional copies in the genome or on one or more vectors.
[0070] In one example, the polynucleotide sequence encoding one or more genes in one or more vectors is understood to be operably linked to one or more inducible promoters. It is generally understood that any promoter that allows expression of the polynucleotide sequence can be used. Examples of promoters include, but are not limited to, T7 RNA polymerase promoter, lac promoter, araBAD promoter, tac promoter, λcI857-PL promoter, and T5 promoter.
[0071] In some instances, the promoter can be an inducible promoter. In one instance, the promoter can be naturally induced. In one instance, the promoter can be modified to be inducible. It should be appreciated that any suitable inducible promoter system can be used. The inducible promoter system can be induced by an inducer or stimulus, including but not limited to chemical inducers, light or heat.
[0072] In one example, the polynucleotide sequence is operably linked to one or more inducible promoters in one or more vectors and operably linked to non-inducible promoters in other vectors. For example, polynucleotide sequences encoding one or more genes of the mevalonate pathway and the lycopene pathway are operably linked to inducible promoters in two vectors, while polynucleotide sequences encoding one or more genes of the α-ionone pathway and one or more hydroperoxide reductase or catalase genes are operably linked to non-inducible promoters in two vectors. In another example, polynucleotide sequences encoding one or more genes of the mevalonate pathway, the lycopene pathway, the α-ionone pathway, and one or more hydroperoxide reductase or catalase genes are operably linked to inducible promoters in four vectors. In yet another example, polynucleotide sequences encoding one or more genes of the mevalonate pathway are operably linked to an inducible promoter in one vector, and polynucleotide sequences encoding one or more genes of the lycopene pathway, the α-ionone pathway, and one or more hydroperoxide reductase or catalase genes are operably linked to non-inducible promoters in two vectors.
[0073] In one example, the polynucleotide sequence encoding one of the plurality of genes is operably linked to one or more inducible promoters. In one example, the inducible promoter is a variant of a T7 promoter or a wild-type T7 promoter. A variant of a wild-type T7 promoter can be generated via mutations to the wild-type promoter. In one example, T7 promoter variants can include, but are not limited to, TM1, TM2, and TM3. It is generally understood that each of the polynucleotide sequences comprising one or more genes of a mevalonate pathway, a lycopene pathway, an α-ionone pathway, and one or more hydroperoxide reductase or catalase genes can be operably linked to an inducible promoter, and different combinations of inducible promoters can be used with each vector of the present invention. For example, the inducible promoter in a vector comprising one or more genes of the mevalonate pathway is TM2, the inducible promoter in another vector comprising one or more genes of the mevalonate pathway is TM3, the inducible promoter in another vector comprising one or more genes of the lycopene pathway is TM1, and the inducible promoter in another vector comprising one or more genes of the α-ionone pathway and one or more hydroperoxide reductase and catalase genes is TM1. The inducible promoter in a vector comprising one or more genes of the mevalonate pathway is TM3, the inducible promoter in another vector comprising one or more genes of the mevalonate pathway is TM1, the inducible promoter in another vector comprising one or more genes of the lycopene pathway is TM2, and the inducible promoter in another vector comprising one or more genes of the α-ionone pathway and one or more hydroperoxide reductase and catalase genes is TM2. It should be understood that the above examples are not exhaustive and are intended only to illustrate the different combinations of polynucleotide sequences that can be operably linked to promoters.
[0074] In one example, the host cell is modified to not express at least one gene involved in amino acid synthesis. The host cell may be modified to not express one, two, three, four, five, six, seven, eight or more genes involved in amino acid synthesis. In another example, the host cell may be modified to express at least one gene involved in amino acid synthesis at a lower level compared to the baseline level. For example, the host cell may be modified to express one, two, three, four, five, six, seven, eight or more genes involved in amino acid synthesis at a lower level compared to the baseline level. The baseline level is understood to be the expression level of at least one gene in the unmodified host cell. In one example, at least one gene involved in amino acid synthesis includes but is not limited to aroA, aroB, aroC and serC.
[0075] In one example, the host cell is a bacterial cell. In another example, the host cell is a bacterial cell comprising a T7 polymerase. In yet another example, the bacterial cell is an Escherichia coli cell. The Escherichia coli cell can be a BL21 Gold DE3 strain, K-12 (RV308), K-12 (HMS174), K-12 substr. MG1655, W strain (ATCC 9637), JM109 (DE3), BW25113, JM109 DE3 or Mach1. In one example, the Escherichia coli cell is a BL21 Gold DE3 strain. In another example, the Escherichia coli cell is a BL21 Gold DE3 ΔaroABC ΔserC strain.
[0076] In one example, the E. coli host cell comprises:
[0077] a) a first vector comprising a polynucleotide sequence encoding atoB, hmgS and truncated hmgR genes of the mevalonate pathway and CCD1 gene of the α-ionone pathway operably linked to a TM2 promoter;
[0078] b) a second vector comprising a polynucleotide sequence encoding mevk, pmk, pmd, idi genes of the mevalonate pathway operably linked to a TM3 promoter;
[0079] c) a third vector comprising a polynucleotide sequence encoding crtBI, IspA and GGPPs genes of the lycopene pathway operably linked to a TM1 promoter; and
[0080] d) A fourth vector comprising a polynucleotide sequence encoding LCYe, CCD1 gene and hydroperoxide reductase gene of the α-ionone pathway operably linked to a TM2 promoter.
[0081] In another aspect, a method of producing one or more apocarotenoids is provided, comprising culturing a host cell described herein in a culture medium.
[0082] In one example, α-ionone is also isolated from the culture medium.
[0083] The one or more apocarotenoids may include, but are not limited to, α-ionone, β-ionone, ψ-ionone, 6-methyl-5-hepten-2-one, hydroxyionone, retinol, and retinal.
[0084] In one example, the method can produce at least one, at least two, at least three, at least four, at least five, at least six, and at least seven apocarotenoids. In a preferred example, at least one apocarotenoid is α-ionone.
[0085] In one example, the host cells are cultured in a culture medium in a snap tube or a batch culture medium or a fed-batch fermentation medium in a flask or bioreactor. It is generally understood that the host cells can be cultured under conditions suitable for host cell growth and propagation and host cell production of apocarotenoids. It is also generally understood that the host cells can be cultured in a culture medium containing components suitable for host cell growth and propagation and host cell production of apocarotenoids.
[0086] In one example, the culture medium may include, but is not limited to, an inducer and one or more carbon substrates. The culture medium may also include one or more antibiotics.
[0087] In one example, the inducing agent in the culture medium capable of inducing the inducible promoter linked to each vector may be lactose or isopropyl β-D-1-thiogalactoside (IPTG).
[0088] In one example, the one or more carbon substrates are glucose, glycerol, or both. In one example, the at least one antibiotic may include, but is not limited to, ampicillin, chloramphenicol, kanamycin, and spectinomycin.
[0089] In one example, the batch culture medium in the culture medium in the Snape pipe or the flask or the bioreactor comprises glucose, glycerine, lactose, ampicillin, chloramphenicol, kanamycin and spectinomycin. In one example, the concentration of glucose is about 1g / L to about 10g / L, the concentration of glycerine is about 1g / L to about 10g / L, and the concentration of lactose is about 10mM to about 30mM. The concentration of glucose can be about 1g / L, about 2g / L, about 3g / L, about 4g / L, about 5g / L, about 6g / L, about 7g / L, about 8g / L, about 9g / L and about 10g / L. In one example, the concentration of glycerine can be about 1g / L, about 2g / L, about 3g / L, about 4g / L, about 5g / L, about 6g / L, about 7g / L, about 8g / L, about 9g / L and about 10g / L. The concentration of lactose can be about 10 mM, about 15 mM, about 20 mM, about 25 mM and about 30 mM. In a preferred example, the concentration of glucose is about 2 g / L, the concentration of glycerol is about 8 g / L, and the concentration of lactose is about 15 mM.
[0090] In one example, host cells as described herein are cultured in a fed-batch fermentation medium comprising IPTG and glucose. In one example, the concentration of glucose is about 1 g / L to about 10 g / L, and the concentration of IPTG is about 0.01 mM to about 0.2 mM. The concentration of glucose can be about 1 g / L, about 2 g / L, about 3 g / L, about 4 g / L, about 5 g / L, about 6 g / L, about 7 g / L, about 8 g / L, about 9 g / L, and about 10 g / L. The concentration of IPTG can be about 0.01mM, about 0.02mM, about 0.03mM, about 0.04mM, about 0.05mM, about 0.06mM, about 0.07mM, about 0.08mM, about 0.09nM, about 0.1mM, about 0.11mM, about 0.12mM, about 0.13mM, about 0.14mM, about 0.15mM, about 0.16nM, about 0.17nM, about 0.18mM, about 0.19mM and about 0.2mM. In a preferred embodiment, the concentration of glucose is about 5g / L and the concentration of IPTG is about 0.1mM.
[0091] During the growth of the host cells, the carbon substrate can be supplemented in the fed-batch fermentation medium. For example, when the host cells have been cultured for a fixed time or the host cells have grown to an optimal density, the carbon substrate, magnesium sulfate and an inducer can be supplemented in the fed-batch fermentation medium.
[0092] In an example, supplementary concentration is about 200g / L to about 700g / L glucose and concentration is about 1g / L to about 10g / L magnesium sulfate in fed batch fermentation medium.The concentration of glucose can be about 200g / L, about 300g / L, about 400g / L, about 500g / L, about 600g / L and about 700g / L.In a preferred example, the concentration of glucose is about 500g / L.In an example, the concentration of magnesium sulfate can be about 1g / L, about 2g / L, about 3g / L, about 4g / L, about 5g / L, about 6g / L, about 7g / L, about 8g / L, about 9g / L and about 10g / L.In a preferred example, the concentration of magnesium sulfate is about 5g / L.
[0093] In one example, when the host cells grow to an optical density of about 10-50, the inducing agent is further supplemented in the fed-batch fermentation medium. The optical density can be about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45 and about 50. In one example, the optical density is about 40. In one example, the inducing agent is IPTG. The concentration of IPTG is about 0.01mM to about 0.2mM. The concentration of IPTG is about 0.01mM, about 0.02mM, about 0.03mM, about 0.04mM, about 0.05mM, about 0.06mM, about 0.07mM, about 0.08mM, about 0.09nM, about 0.1mM, about 0.11mM, about 0.12mM, about 0.13mM, about 0.14mM, about 0.15mM, about 0.16nM, about 0.17nM, about 0.18mM, about 0.19mM and about 0.2mM. In a preferred embodiment, the concentration of IPTG is about 0.1mM.
[0094] In one example, the fed-batch fermentation medium is maintained at about pH 6.5 to about pH 7.5. In a preferred example, the fed-batch fermentation medium is maintained at about pH 7.
[0095] In one example, the host cells are cultured in a culture medium at a shaking speed of about 50 rpm to about 2000 rpm. In one example, the host cells are cultured in a culture medium in a snap tube or a batch culture medium in a flask at a shaking speed of about 50 rpm to about 500 rpm. In a preferred example, the host cells are cultured in a culture medium in a snap tube or a batch culture medium in a flask at a shaking speed of about 100 rpm to about 300 rpm. The host cells are cultured in a batch culture medium in snap tubes and flasks at a shaking speed of about 300 rpm.
[0096] In another example, with an oscillation speed of about 100rpm to about 2000rpm, the host cells are cultured in a culture medium in a bioreactor. In one example, the bioreactor is a personalized bioreactor. It should be generally understood that personalized bioreactors accommodate small volumes of culture medium, such as less than about 50mL, less than about 40mL, less than about 30mL, less than about 20mL, less than about 10mL, less than about 5mL, less than about 2mL or less than about 1mL. In a preferred example, with an oscillation speed of about 250rpm to about 500rpm, the host cells are cultured in a culture medium in a bioreactor. In a preferred example, with an oscillation speed of about 500rpm, the host cells are cultured in a culture medium in a bioreactor.
[0097] α-ionone can be extracted from the culture medium. In one example, the fed-batch fermentation medium is further supplemented with sunflower oil to extract α-ionone. In another example, the culture medium in the snap tube or the batch culture medium in the flask is supplemented with dodecane to extract α-ionone.
[0098] In one example, the productivity of α-ionone in a fed-batch fermentation medium is at least 500 mg / L. The productivity of α-ionone in a fed-batch fermentation medium is at least 500 mg / L, at least 550 mg / L, at least 600 mg / L, at least 650 mg / L, at least 700 mg / L, at least 750 mg / L, at least 800 mg / L, at least 850 mg / L, and at least 900 mg / L. In a preferred example, the productivity of α-ionone is at least 700 mg / L.
[0099] In one example, the yield of α-ionone in the batch medium and the fed-batch fermentation medium in the flask is determined based on the titer per OD600 (titer / OD600). In one example, the titer per OD600 is about 3 mg / L / OD 600 To about 5mg / L / OD 600 The titer per OD600 can be about 3 mg / L / OD 600 , about 3.5mg / L / OD 600 , about 4mg / L / OD 600 , about 4.5mg / L / OD 600 and about 5mg / L / OD 600 .
[0100] In another aspect, a kit for producing one or more apocarotenoids is provided, wherein the kit comprises a host cell as described herein and instructions for use.
[0101] In one example, the host cells are dissolved in solution or are freeze-dried. In another example, the host cells are preserved by deep freezing.
[0102] The invention illustratively described herein may be suitably practiced in the absence of any element or elements, limitation or limitations not specifically disclosed herein. Thus, for example, the terms "comprising", "including", "containing", and the like should be interpreted broadly and without limitation. Furthermore, the terms and expressions used herein have been used as terms of description, rather than terms of limitation, and when using these terms and expressions, it is not intended to exclude any equivalents of the features shown and described, or portions thereof, but it should be recognized that various modifications are possible within the scope of the claimed invention. Therefore, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, those skilled in the art may resort to modifications and variations of the invention embodied therein disclosed herein, and such modifications and variations are considered to be within the scope of the present invention.
[0103] The present invention has been described extensively and generically herein. Each narrower category and subgeneric grouping that falls within the generic disclosure also forms a part of the present invention. This includes generic description of the present invention in the context of a proviso or negative limitation that deletes any subject matter from the generic concept, regardless of whether the deleted material is specifically described herein.
[0104] Other embodiments are within the following claims and non-limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0105] Experimental Section
[0106] Non-limiting examples and comparative examples of the present invention will be further described in more detail with reference to specific examples, which should not be construed as limiting the scope of the present invention in any way.
[0107] Materials and methods
[0108] Bacterial strains, plasmids, and oligonucleotides
[0109] Table 1 lists the strains and plasmids used in this study. Specific oligonucleotides used for PCR amplification were synthesized by Integrated DNA Technologies (IDT) and are listed in Table 2. Briefly, to construct module 4-7 (p15A-amp-ΔN50LsLCYe-OfCCD1-trxA(TM1) with three mutations in the OfCCD1 active site loop, katG was added) and module 4-8 (p15A-amp-ΔN50LsLCYe-OfCCD1-trxA(TM1) with three mutations in the OfCCD1 active site loop, ahpC / F was added). The backbone was amplified using module 4-1 as a template, and the genes for katG and ahpC / F were amplified from Escherichia coli BL21. iProof TM High-Fidelity DNA Polymerase (BIO-RAD) was used for cloning.
[0110] Table 1. Strains and plasmids used in this study
[0111]
[0112]
[0113] Table 2. Oligonucleotides used for PCR amplification
[0114]
[0115]
[0116] Culture medium and culture conditions
[0117] All cells were grown in LB medium. For production tests, a chemically defined Auto-induction medium containing 2 g / L glucose and 8 g / L glycerol, 2 g / L ammonium sulfate, 4.2 g / L KH2PO4, 11.24 g / L K2HPO4, 1.7 g / L citric acid, 0.5 g / L MgSO4, and 10 mL / L trace element solution was used. The trace element solution (100×) contained 0.25 g / L CoCl2·6H2O, 1.5 g / L MnSO4·4H2O, 0.15 g / L CuSO4·2H2O, 0.3 g / L H3BO3, 0.25 g / L Na2MoO4·2H2O, 0.8 g / L Zn(CH3COO)2, 5 g / L Fe(III) citric acid, and 0.84 g / L ethylenediaminetetraacetic acid (EDTA), pH 8.0. The cells were induced with 15 mM lactose. Briefly, 1% of the fresh cell culture was inoculated into 1 ml of defined autoinduction medium in a 14 ml snap cap falcon or 10 ml of defined autoinduction medium in a 100 ml flask. After induction, the culture was supplemented with 200 μl (1 ml culture) and 10 ml (10 ml culture) dodecane to extract ionones, and the cells were harvested after incubation at 28° C. with a shaking speed of 100 rpm or 300 rpm for 72 hr. To maintain the corresponding plasmids, the culture medium was supplemented with appropriate antibiotics (100 mg / L ampicillin, 34 mg / L chloramphenicol, 50 mg / L kanamycin, 50 mg / L spectinomycin).
[0118] Quantification of α-ionone and MHO
[0119] α-ionone or MHO samples were prepared by diluting the organic layer 10-50 times in 1,000 μl of hexane. GC-MS analysis of the samples was performed on an Intuvo 9000 GC system connected to a 5977B MS detector (Agilent Technologies, USA). The system was equipped with a polar DB wax column (polyethylene glycol (PEG); 30m x 0.25mm IDx 0.25μm: Agilent Technologies, USA) and a split injector (split ratio 1:10). The oven program started at 80°C for 1 min, then increased to 130°C at 20°C / min for 1.5 min, then increased to 200°C at 40°C / min for 2 min, and finally increased at 80°C / min and maintained at 230°C for another 2 min. Helium was used as the carrier gas with a constant flow rate of 1.0 mL / min. The Agilent 5977B mass spectrometer was operated in electron ionization mode at 70 eV, the source temperature was 230 °C, the transfer line temperature was set to 250 °C, the scan range was m / z 50-500 in full scan mode, and the acquisition rate was 3.6 scans / second. The column wash solvent was methanol, while hexane was used for needle wash. The injection volume was 1 μL. The ionone concentration was calculated by interpolation of a standard curve prepared with commercial standards. The mass spectrometer was operated in EI mode for full scan analysis.
[0120] ROS-Glo TM H2O2 determination
[0121] The H2O2 production was quantified using ROS-Glo (Promega, Madison, WI, USA) according to the supplier's instructions. AI_2211 and AI_2218 were inoculated in 1 ml of auto-inducing R-medium by RTS-1C (Personal Bioreactor, Biosan). The cells were grown to OD 600 The culture was then incubated for 1.5 hr before the cells were harvested and the amount of luciferin precursor produced was measured. The H2O2 substrate reacts directly with H2O2 to produce luciferin precursor. TM ROS-Glo with recombinant luciferase and d-cysteine TM Detection Reagent(ROS-Glo TM After the precursor is converted to luciferin by d-cysteine, the generated luciferin reacts with Ultra-Glo TM Recombinant luciferase reaction generates a luminescent signal proportional to the H2O2 concentration. (ROS-Glo TMH2O2 Assay, Promega). Briefly, 800 μl of cells were incubated with 200 μl of H2O2 substrate, and then ROS-Glo detection reagent was added. Luminescence corresponding to H2O2 levels was measured using a microplate reader (Molecular Devices, San Jose, CA, USA).
[0122] Fed-batch fermentation
[0123] The starting medium was a modified chemically defined medium containing 5 g / L glucose, which was transferred to a 5 L bioreactor with an initial working volume of 1.8 L. The chemically defined medium also contained 2 g / L (NH4)2SO4, 4.2 g / L KH2PO4, 11.24 g / L K2HPO4, 1.7 g / L citric acid, 0.5 g / L MgSO4, and 10 ml / l trace element solution, pH 7.0. Trace element solution (100X) contains 0.25g / L CoCl2·6H2O, 1.5g / L MnSO4·4H2O, 0.15g / L CuSO4·2H2O, 0.3g / L H3BO3, 0.25g / L Na2MoO4·2H2O, 0.8g / L Zn(CH3COO)2, 5g / L Fe(III) citric acid and 0.84g / LEDTA, pH 8.0. Escherichia coli strain AI_2218 is inoculated into sterile defined medium to obtain an initial optical density (or OD600) of 0.1 at 600nm. First, fermentation is carried out at 7.0, 37°C and 30% respectively at the control set points of pH, temperature and dissolved oxygen. After inoculation, peristaltic pumping of the feed stock solution (containing 500 g / L glucose and 5 g / L MgSO4) was also started at a flow rate of 1.62 mL / h overnight (about 13 h). Throughout the experiment, the pH of the culture was controlled at 7.0 using an alkaline solution (a mixture of 28% ammonium hydroxide and 1 M sodium hydroxide solution; in a 1:1 volume ratio). When OD600 reached about 40, the cells were induced with 0.1 mM IPTG, and then 500 mL of sunflower oil was added to the bioreactor as an extractant.
[0124] result
[0125] Example 1
[0126] Oxygen sensitivity of the new strain AI_2211:
[0127] Previously, a biosynthetic pathway for producing α-ionone was constructed in Escherichia coli. The biosynthetic pathway consists of 4 modules, including: 1. Upstream mevalonate pathway, 2. Downstream mevalonate pathway, 3. Lycopene pathway and 4. α-ionone pathway. According to the modification of the pathway, the strain producing α-ionone was named AI_ABCD (Table 1). In order to increase the production of α-ionone, additional copies of CCD1 were overexpressed to enhance the conversion of ε-carotene to α-ionone, and the expression levels of pathway genes were re-optimized. The AI_2211 strain was tested under three different conditions, A: 1ml defined medium, 300rpm, in a Snap tube. B: 10ml defined medium, 100rpm, flask. C: 10ml defined medium, 300rpm, flask, to understand the yield of the strain when we scale up from 1ml to 10ml ( Figure 2 A). The results showed that as the shaking speed increased, both the titer and content of α-ionone decreased. It is not clear whether the negative effect of shaking speed on α-ionone production is due to the extra copy of CCD1 on the plasmid present in AI_2211. Therefore, to test this hypothesis, the extra CCD1 was removed while keeping the rest of the genes the same as AI_2211 to obtain the AI_3211 strain (Table 1). The two strains were compared in flasks at 100 rpm and 300 rpm. Interestingly, the amount of α-ionone produced by the AI_3211 strain at 300 rpm was higher than at 100 rpm. In contrast, the amount of α-ionone produced by the AI_2211 strain at 100 rpm was about 4 times that at 300 rpm ( Figure 2 B). Higher shaking speeds contribute to higher amounts of dissolved oxygen in the flasks and potentially higher oxidative stress. Therefore, it was hypothesized that this phenomenon could be attributed to the generation of reactive oxygen species (ROSs), especially H2O2.
[0128] In vivo overexpression of catalase genes; catalase G (katG): AI_2217 and H2O2 production by alkyl hydroperoxide reductase (ahpC / F): AI_2218
[0129] To test this hypothesis, katG (catalase G) was overexpressed as AI_2217, and ahpC / F (alkyl hydroperoxide reductase) was overexpressed as AI_2218 (Table 1). Based on the comparison of the two strains, AI_2218 gave a higher α-ionone titer at higher shaking speeds. However, AI_2217 showed the same trend as AI_2211, but the amount of α-ionone at 100 rpm was about twice that at 300 rpm ( Figure 2B). In summary, the α-ionone titers of different strains AI_2211, AI_3211, AI_2217, and AI_2218 were compared. The results showed that the α-ionone titers of AI_3211 and AI_2218 were positively correlated with the oscillation speed, while in contrast, the α-ionone titers of AI_2211 and AI_2217 were negatively correlated with the oscillation speed ( Figure 2 B) In addition, AI_2211 and AI_2218 were used in 1 ml of defined medium to generate the TM H2O2 assay measured H2O2 production. Due to the small amount of culture medium, flasks were not used and the experiment was carried out by RTS-1C at 250rpm and 500rpm. The results showed that the H2O2 concentration was about 40000RLU under AI_2211 and 500rpm, which was 1.6 times that of AI_2211 and 250rpm and AI_2218 and two speeds ( Figure 3 ). The measurement results of H2O2 concentration showed that AI_2211 was associated with more oxidative stress of H2O2 at high stirring rates; in addition, it was demonstrated that AI_2218 eliminated H2O2 more efficiently due to ahpC / F overexpression.
[0130] Apocarotenoids: MHO production of AI_2211 and AI_2218 under different oscillation speeds
[0131] Next, the effect of H2O2 on the α-ionone production pathway in AI_2211 and the further reduction of α-ionone production in AI_2211 were investigated. Based on previous experiments, it was observed that the color of AI_2211 pellets was orange and white at 100 rpm and 300 rpm, respectively ( Figure 4 ). The color of naturally occurring lycopene is red and the color of ε-carotene is yellow. Therefore, it was hypothesized that H2O2 might degrade some of the intermediate compounds of the pathway, such as lycopene and ε-carotene, thereby reducing the pathway flux towards α-ionone production. From experiments in which AI_2211 and AI_2218 were inoculated at 100 rpm and 300 rpm, the presence of 6-methyl-5-hepten-2-one (MHO), an important flavor and aroma volatile in a variety of fruits such as tomatoes, was observed. The production of MHO was compared with α-ionone, and the cell pellets were collected to analyze the different colors. The ratio of MHO to α-ionone of the AI_2211 strain at 300 rpm was around 0.5, which was twice that of all other tests performed (around 0.2-0.3) ( Figure 4). These results indicate that for the AI_2211 strain, at higher shaking rates, MHO concentrations did increase and were associated with decreased α-ionone production. Moreover, substrate degradation was evidenced by the color of the pellets for AI_2211 at 300 rpm, which was colorless compared to AI_2211 at 100 rpm and AI_2218 at 300 rpm. The orange color of the pellets for AI_2211 and AI_2218 at 100 rpm suggests that the pellets may be mixed with lycopene and ε-carotene. The color of the pellets for AI_2218 at 300 rpm was yellow, suggesting that most of it was ε-carotene ( Figure 4 , 6 ).
[0132] AI_2218, bioreactor fermentation for α-ionone production
[0133] Before scaling up to a 5-L bioreactor, strains AI_0000, AI_2211, and AI_2218 were compared in flasks at 300 rpm to determine which strain produced the highest α-ionone titer ( Figure 8 ). The results showed that AI_2218 achieved the highest α-ionone titer compared to AI_0000 and AI_2211. In contrast, AI_2211 produced the highest amount of α-ionone at 100 rpm. However, due to its extremely high sensitivity to oxygen, it may be challenging to expand the AI_2211 strain. In contrast, AI_2218 produced the highest amount of α-ionone at high oscillation rates, which is the most promising condition for expansion. Subsequently, 5L bioreactor experiments were conducted with AI_2218 and demonstrated the production of approximately 700 mg / l of α-ionone ( Figure 5 ).
[0134] Table 1 below summarizes the polypeptide and polynucleotide sequences used in the present invention.
[0135] Table 3. Summary of sequence listing
[0136]
[0137]
[0138]
[0139]
[0140]
[0141]
[0142]
[0143] Equivalence
[0144] The above examples are provided to illustrate the purpose of the present invention and should not be construed as imposing any limitation on the scope of the present invention. It is obvious that, without departing from the basic principle of the present invention, many modifications and changes can be made to the specific embodiments of the present invention described above and in the examples. All these modifications and changes are intended to be included by the application.
Claims
1. A host cell comprising one or more vectors comprising a polynucleotide sequence encoding: one or more genes of the mevalonate pathway; one or more genes of the lycopene pathway; one or more genes of the α-ionone pathway; and One or more hydroperoxide reductase or catalase genes.
2. The host cell of claim 1, wherein the one or more genes of the mevalonate pathway are selected from hmgS, atoB, hmgR, mevK, pmk, pmd and idi, wherein the hmgR gene is optionally truncated.
3. The host cell according to claim 1 or 2, wherein the one or more genes of the lycopene pathway are selected from the group consisting of crtBI, crtB, crtI, farnesyl diphosphate synthase genes and geranylgeranyl diphosphate synthase (GGPPs) genes.
4. A host cell according to claim 3, wherein the GGPPs gene is isolated from a prokaryotic organism, wherein the prokaryotic organism is an archaea including Methanocaldococcus jannaschii or Methanococcus maripaludis, or a bacterium including Methanobacterium or Deinococcus radioduran.
5. The host cell according to claim 4, wherein the bacterium is Methanobacterium.
6. The host cell according to any one of claims 1 to 5, wherein the one or more genes of the α-ionone pathway are selected from the group consisting of a lycopene cyclase gene and a CCD gene.
7. The host cell according to any one of claims 1 to 6, wherein the one or more vectors further comprise a polynucleotide sequence encoding one or more additional carotenoid cleavage dioxygenase (CCD) genes of the α-ionone pathway.
8. The host cell according to claim 6 or 7, wherein the CCD gene is CCD1 or CCD4 gene, or a combination thereof. 9 . The host cell according to claim 8 , wherein the one or more CCD1 genes are isolated from a plant selected from the group consisting of Osmanthus fragrans, Arabidopsis thaliana, Vitis vinifera and Petunia hybrid or a combination thereof.
10. The host cell according to claim 9, wherein one or more of the CCD1 genes are isolated from Osmanthus fragrans, optionally wherein one or more of the CCD1 genes isolated from Osmanthus fragrans (OfCCD1) are fused with an N-terminal fusion partner, optionally wherein one or more of the OfCCD1 genes comprise the polypeptide sequence shown in SEQ ID NO:
1.
11. The host cell according to claim 10, wherein one or more of the OfCCD1 genes are mutated in the loop of the active site, optionally wherein the mutation is located at one or more amino acid positions, optionally wherein one or more mutations comprise the polynucleotide sequence shown in SEQ ID NO:
2.
12. The host cell according to claim 11, wherein the mutations are substitution of lysine at position 425 by serine, substitution of aspartic acid at position 424 by asparagine, and substitution of lysine at position 428 by alanine.
13. The host cell according to any one of claims 10-12, wherein one or more of the OfCCD1 genes are truncated.
14. The host cell according to any one of claims 10-13, wherein the N-terminal fusion partner is selected from small ubiquitin-like modifier protein, maltose binding protein and thioredoxin (trxA), optionally wherein the N-terminal fusion partner is trxA.
15. The host cell according to any one of claims 10-14, wherein one or more of the OfCCD1 and trxA genes are overexpressed.
16. The host cell according to any one of claims 6 to 15, wherein the lycopene cyclase gene is a lycopene ε-cyclase (LCYe) gene.
17. The host cell according to claim 16, wherein the LCYe gene is isolated from a plant selected from the group consisting of lettuce (Lactuca sativa), Arabidopsis thaliana, tobacco (Nicotiana tabacum) and cabbage (Brassica oleracea var. capitata).
18. The host cell according to claim 16 or 17, wherein the LCYe gene isolated from lettuce is truncated at the N-terminus.
19. The host cell according to claim 18, wherein the LCYe is truncated from amino acids 1 to 50, optionally wherein the truncated LCYe comprises the polynucleotide sequence shown in SEQ ID No:
3.
20. The host cell of any one of claims 1-19, wherein the hydroperoxide reductase or catalase gene is isolated from a prokaryotic organism, optionally wherein the prokaryotic organism is Escherichia coli.
21. The host cell of claim 20, wherein the hydroperoxide reductase isolated from Escherichia coli is an alkyl hydroperoxide reductase (ahpC / F), wherein the catalase isolated from Escherichia coli is catalase G (KatG).
22. The host cell of claim 21, wherein the KatG or ahpC / F is overexpressed.
23. according to the host cell described in any one of claims 1-22, wherein said one or more genes are operably linked to one or more inducible promoters, wherein said inducible promoter is a T7 promoter, optionally wherein said T7 promoter is a variant of a wild-type T7 promoter.
24. The host cell of any one of claims 1-23, wherein the host cell is modified not to express at least one gene involved in amino acid synthesis.
25. The host cell of claim 24, wherein the at least one gene involved in amino acid synthesis is aroA, aroB, aroC and serC.
26. The host cell of any one of claims 1-25, wherein the host cell is a bacterial cell.
27. The host cell of claim 26, wherein the bacterial cell is an E. coli cell.
28. A method of producing one or more apocarotenoids, comprising culturing the host cell of any one of claims 1-27 in a culture medium.
29. The method of claim 28, wherein the one or more apocarotenoids are selected from the group consisting of α-ionone, β-ionone, ψ-ionone, 6-methyl-5-hepten-2-one, hydroxyionone, retinol, and retinal.
30. The method of claim 28 or 29, wherein the culture medium comprises an inducing agent and one or more carbon substrates, optionally wherein the culture medium comprises at least one antibiotic.
31. The method of claim 30, wherein the inducing agent is IPTG or lactose, wherein the one or more carbon substrates are glucose, glycerol, or both, and wherein the at least one antibiotic is selected from the group consisting of ampicillin, chloramphenicol, kanamycin, and spectinomycin.
32. The method of any one of claims 28-31, wherein the host cells are cultured in the culture medium at a shaking speed of about 50 rpm to about 2000 rpm.
33. A process according to any one of claims 28 to 32, wherein the yield of α-ionone in the fed-batch fermentation medium is at least 500 mg / L, optionally wherein the yield of α-ionone is at least 700 mg / L.
34. The method of any one of claims 28-33, wherein the yield of α-ionone in batch medium and fed-batch fermentation medium in flasks is measured by titer per OD600 (titer / OD600), optionally wherein the titer per OD600 is about 3-5 mg / L / OD600.
35. A kit for producing one or more apocarotenoids, wherein the kit comprises the host cell of any one of claims 1-27 and instructions for use.
36. The kit of claim 35, wherein the host cells are dissolved in solution or lyophilized.
37. The kit of claim 36, wherein the host cells are preserved by deep freezing.
